Skip to main content
Erschienen in: Medical Oncology 9/2019

01.09.2019 | Original Paper

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer

verfasst von: Daniela Zanini, Leandro Henrique Manfredi, Luana Paula Pelinson, Victor Camera Pimentel, Andréia Machado Cardoso, Viviane do Carmo Araújo Gonçalves, Cláudia Bertoncelli dos Santos, Jessié Martins Gutierres, Vera Maria Morsch, Daniela Bitencourt Rosa Leal, Maria Rosa Chitolina Schetinger

Erschienen in: Medical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Cigarette smoking is directly associated with lung cancer. Non-small cell lung carcinoma (NSCLC) represents approximately 80% from all types of lung cancer. This latter is hard to diagnose and to treat due to the lack of symptoms in early stages of the disease. The aim of this study was to evaluate ADA activity and the expression of P2X7, A1, and A2A receptors and in lymphocytes. In addition, the profile of pro-inflammatory and anti-inflammatory cytokines serum levels of patients with lung cancer in advanced stage was evaluated. Patients (n = 13) previously treated for lung cancer at stage IV (UICC) with chemotherapy had their blood collected. Cancer patients showed a decrease in ADA activity and an increase in A1 receptor expression in lymphocytes when compared to the control group. Moreover, patients exhibited an increase in IL-6 and TNF-α, while IL-17 and INF-ϒ serum levels were lower in patients with lung cancer. The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-α and decreasing IL-17 and INF-γ serum levels. Our data show an indirect evidence that purinergic signaling may have a role in promoting a profile of cytokines levels that favors tumor progression.
Literatur
2.
Zurück zum Zitat CP SBW. World Cancer Report. IARC Press. 2014:350-2. CP SBW. World Cancer Report. IARC Press. 2014:350-2.
4.
Zurück zum Zitat Roca M, Roca IC, Mihaescu T. Lung cancer—a comorbidity in chronic obstructive pulmonary disease. Rev Med Chir Soc Med Nat Iasi. 2012;116(4):1055–62.PubMed Roca M, Roca IC, Mihaescu T. Lung cancer—a comorbidity in chronic obstructive pulmonary disease. Rev Med Chir Soc Med Nat Iasi. 2012;116(4):1055–62.PubMed
7.
Zurück zum Zitat Onuchic AC, Chammas R. Câncer e o microambiente tumoral. Rev Med (São Paulo). 2010;89(1):21–31.CrossRef Onuchic AC, Chammas R. Câncer e o microambiente tumoral. Rev Med (São Paulo). 2010;89(1):21–31.CrossRef
9.
Zurück zum Zitat Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28(12):740–4.CrossRefPubMed Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28(12):740–4.CrossRefPubMed
10.
Zurück zum Zitat De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res. 1998;17(4):413–7.PubMed De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res. 1998;17(4):413–7.PubMed
13.
Zurück zum Zitat Spychala J. Tumor-promoting functions of adenosine. Pharmacol Therap. 2000;87(2–3):161–73.CrossRef Spychala J. Tumor-promoting functions of adenosine. Pharmacol Therap. 2000;87(2–3):161–73.CrossRef
14.
Zurück zum Zitat Burnstock G. Purinergic signalling—an overview. Novartis Foundation symposium. 2006;276:26–48; discussion -57, 275–81. Burnstock G. Purinergic signalling—an overview. Novartis Foundation symposium. 2006;276:26–48; discussion -57, 275–81.
18.
Zurück zum Zitat Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg’s Arch Pharmacol. 2000;362(4–5):299–309.CrossRef Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg’s Arch Pharmacol. 2000;362(4–5):299–309.CrossRef
20.
Zurück zum Zitat Decking UK, Schlieper G, Kroll K, Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res. 1997;81(2):154–64.CrossRefPubMed Decking UK, Schlieper G, Kroll K, Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res. 1997;81(2):154–64.CrossRefPubMed
22.
Zurück zum Zitat Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Investig Suppl. 1968;97:77–89. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Investig Suppl. 1968;97:77–89.
23.
Zurück zum Zitat Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
26.
Zurück zum Zitat INCA. Instituto Nacional do Câncer José Alencar Gomes da Silva. 2016. INCA. Instituto Nacional do Câncer José Alencar Gomes da Silva. 2016.
30.
Zurück zum Zitat Duarte RL, Paschoal ME. Molecular markers in lung cancer: prognostic role and relationship to smoking. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2006;32(1):56–65.CrossRef Duarte RL, Paschoal ME. Molecular markers in lung cancer: prognostic role and relationship to smoking. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2006;32(1):56–65.CrossRef
32.
Zurück zum Zitat Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies—a possible tumor-associated marker. J Cancer Res Clin Oncol. 1986;111(1):54–8.CrossRefPubMed Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies—a possible tumor-associated marker. J Cancer Res Clin Oncol. 1986;111(1):54–8.CrossRefPubMed
35.
Zurück zum Zitat Khoo HE, Ho CL, Chhatwal VJ, Chan ST, Ngoi SS, Moochhala SM. Differential expression of adenosine A1 receptors in colorectal cancer and related mucosa. Cancer Lett. 1996;106(1):17–21.CrossRefPubMed Khoo HE, Ho CL, Chhatwal VJ, Chan ST, Ngoi SS, Moochhala SM. Differential expression of adenosine A1 receptors in colorectal cancer and related mucosa. Cancer Lett. 1996;106(1):17–21.CrossRefPubMed
39.
Zurück zum Zitat Apasov SG, Sitkovsky MV. The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol. 1999;11(2):179–89.CrossRefPubMed Apasov SG, Sitkovsky MV. The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol. 1999;11(2):179–89.CrossRefPubMed
40.
Zurück zum Zitat Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol (Baltimore). 2007;179(3):1884–92. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol (Baltimore). 2007;179(3):1884–92.
41.
Zurück zum Zitat Gelfand EW, Lee JJ, Dosch HM. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci USA. 1979;76(4):1998–2002.CrossRefPubMedPubMedCentral Gelfand EW, Lee JJ, Dosch HM. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci USA. 1979;76(4):1998–2002.CrossRefPubMedPubMedCentral
Metadaten
Titel
ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer
verfasst von
Daniela Zanini
Leandro Henrique Manfredi
Luana Paula Pelinson
Victor Camera Pimentel
Andréia Machado Cardoso
Viviane do Carmo Araújo Gonçalves
Cláudia Bertoncelli dos Santos
Jessié Martins Gutierres
Vera Maria Morsch
Daniela Bitencourt Rosa Leal
Maria Rosa Chitolina Schetinger
Publikationsdatum
01.09.2019
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 9/2019
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-019-1301-1

Weitere Artikel der Ausgabe 9/2019

Medical Oncology 9/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.